Business Context and Reporting Period
Company: Qualigen Therapeutics, Inc. (Note: Request metadata listed "Aixcrypto Holdings, Inc.", but the filing text identifies the registrant as Qualigen Therapeutics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: September 29, 2025
Event: Consummation of a private placement offering and entry into material definitive agreements to establish cryptocurrency treasury operations.
Key Financial Metrics and Transaction Details
- Total Offering Proceeds: $41,000,000 in cash.
- Securities Issued:
- 337,432 shares of Common Stock at $2.246 per share.
- 17,783 shares of Series B Convertible Preferred Stock at $1,000 per share (Stated Value).
- Use of Proceeds:
- Up to $6,800,000 for existing debt repayment and business operations.
- Balance allocated to establishing cryptocurrency treasury operations.
- Placement Agent Fees: 5.5% cash fee of gross proceeds plus warrants for 6% of securities sold (exercise price $2.47). Reimbursement of up to $150,000 in expenses.
- Advisory Compensation: Approximately 60,257 shares of Common Stock (approx. 5% of post-closing outstanding shares) issued to About Investment Pte.
Material Changes and Corporate Actions
- Strategic Pivot: The company is shifting focus to establish cryptocurrency treasury operations using the majority of the raised capital.
- Board Composition Changes:
- Resignations of Cody Price, Campbell Becher, and Robert Lim.
- Appointment of two designees from the Lead Investor (Faraday Future Intelligent Electric Inc.).
- Board size reduced to five members.
- Executive Leadership Changes:
- Jiawei Wang appointed as Co-Chief Executive Officer.
- Koti Meka appointed as Chief Financial Officer.
- Ownership Caps: Allocation of shares was structured so no single purchaser exceeds 19.99% ownership (Exchange Cap).
Guidance, Outlook, and Risks
- Stockholder Approval Requirement: Conversion of Series B Stock is contingent upon stockholder approval (required due to Nasdaq Rule 5635). The company must obtain this approval by October 29, 2025 (or November 28, 2025 if under SEC review).
- Contingency Plan: If approval is not obtained at the first meeting, the company is obligated to hold additional meetings every 90 days until approval is secured.
- Registration Rights: The company must file a resale registration statement within 45 days of closing and use best efforts to have it declared effective within 45 days thereafter.
- Lead Investor Rights: Faraday Future Intelligent Electric Inc. (Lead Investor) has rights to appoint directors proportional to ownership (if >5%), participate in subsequent financings, and receive board observer status if ownership drops below the threshold.
- Financial Data: The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period; it focuses solely on the capital raise transaction.
Investor Verification Checklist
- Verify the outcome of the stockholder vote required for Series B Stock conversion (deadline: Oct/Nov 2025).
- Confirm the specific allocation of the "balance" of proceeds to cryptocurrency assets and the specific digital assets being acquired.
- Review the full text of the Lead Investor Agreement regarding Faraday Future's ongoing influence on board composition and future financing rights.
- Monitor the filing of the resale registration statement (due within 45 days of Sept 29, 2025) to ensure liquidity for new investors.
- Assess the impact of the new executive leadership (Co-CEO Jiawei Wang and CFO Koti Meka) on the company's operational strategy.